BIOMARKER:

HRD + BRCA1 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

HRD + BRCA1 mutation	Ovarian Cancer	HRD + BRCA1 mutation	Ovarian Cancer	bevacizumab + olaparib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) bevacizumab + olaparib Sensitive : C3 ESMO 2022 - 3wk	bevacizumab + olaparib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks bevacizumab + olaparib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HRD + BRCA1 mutation	Ovarian Cancer	HRD + BRCA1 mutation	Ovarian Cancer	niraparib Sensitive: C2 – Inclusion Criteria niraparib Sensitive : C2	niraparib Sensitive: C2 – Inclusion Criteria niraparib Sensitive : C2
HRD + BRCA1 mutation	Peritoneal Cancer	HRD + BRCA1 mutation	Peritoneal Cancer	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3
HRD + BRCA1 mutation	Fallopian Tube Cancer	HRD + BRCA1 mutation	Fallopian Tube Cancer	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3